<DOC>
	<DOC>NCT02497716</DOC>
	<brief_summary>To characterize the pharmacokinetic profile of rivaroxaban administered as granules for suspension formulation and to document safety and tolerability</brief_summary>
	<brief_title>Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Children with an age â‰¥2 months and weight between 3 and &lt;12 kg, who have completed anticoagulant treatment at least 10 days prior to the planned study drug administration. Gestational age at birth of at least 37 weeks Oral feeding/ nasogastric/ gastric feeding for at least 10 days Normal PT and aPTT within 10 days prior to planned study drug administration Written informed consent provided and, if applicable, child assent provided Active bleeding or high risk for bleeding, contraindicating anticoagulant therapy Planned invasive procedures, including removal of central lines, within 24 hours before and after single dose intake An estimate glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2 Hepatic disease which is associated either with: coagulopathy leading to a clinically relevant bleeding risk, or alanine aminotransferase (ALT) &gt; 5x upper level of normal (ULN), or total bilirubin &gt; 2x ULN with direct bilirubin &gt; 20% of the total. Platelet count &lt; 50 x 10^9/L Hypertension (defined as systolic and/or diastolic blood pressure &gt;95th percentile for age) Concomitant use of strong inhibitors of both CYP3A4 and Pglycoprotein, e.g., all human immunodeficiency virus protease inhibitors and the following azoleantimycotic agents: ketoconazole, itraconazole, voriconazole, and posaconazole, if used systemically (fluconazole is allowed) Concomitant use of strong inducers of CYP3A4, e.g., rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine Inability to cooperate with the study procedures Hypersensitivity to rivaroxaban Participation in a study with an investigational drug other than rivaroxaban or a medical device within 30 days prior to treatment History of gastrointestinal disease or surgery associated with impaired absorption</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>